02 Sep CellProthera inches closer to Phase III trial for heart attack cell therapy
Speaking at a press conference, CellProthera’s CEO said the company is moving into the final phase of clinical development for its product.
Author: equipe
30 Aug Navigating the Challenges of Autologous Cell Therapy Production
Revolutionizing Cardiac Regeneration.
30 Aug CellProthera shares U.S. regulatory progress of ProtheraCytes® cell therapy program
Positive pre-IND meeting with FDA helps position CellProthera for a U.S. and international Phase III trial for...
07 Aug CellProthera begins long-term observational study to demonstrate safety and efficacy of ProtheraCytes® cell therapy in acute myocardial infarction
The long-term PERFECT observational study follows patients from successful Phase I/IIb of ProtheraCytes for the repair and...
12 Jul CellProthera and BioCardia Collaborate on Successful Phase II Trial of ProtheraCytes© for the Treatment of Acute Myocardial Infarction
MULHOUSE, France, and SUNNYVALE, California USA - July 8, 2024 CellProthera, a private company specializing in cell-based therapies...
11 Jul CellProthera and BioCardia Collaborate on Phase 2 Trial of ProtheraCytes to Treat AMI
July 8, 2024—France-based CellProthera and BioCardia, Inc., which is headquartered in California, announced findings from the collaborative phase 2 trial of CellProthera’s ProtheraCytes for the treatment of acute myocardial infarction (AMI). Additionally, the companies noted they plan to continue the collaboration into phase 3.
14 Jun Drug Discovery News: A cell therapy to heal a broken heart
Researchers harvest stem cells from patients who have recently had a heart attack and use them to trigger regeneration of their cardiac muscle.
13 Jun Drug Development & Delivery: CellProthera Announces Positive Phase 1/2b Data for ProtheraCytes Cell Therapy in Acute Myocardial Infarction
CellProthera recently announced positive results from a Phase 1/2b study of its lead ProtheraCytes in patients following a severe heart attack, positioning the stem cell therapy as a promising option to repair and regenerate heart tissue. The data was presented today by Faiez Zannad, MD, PhD, Chairman of the study’s steering committee and emeritus professor of therapeutics at the Université of Lorraine.
18 May EPR: Cell therapy could help curb progression of heart failure
New clinical trial data demonstrates the potential for a stem cell treatment as a cardiac regenerative therapy.
14 May CellProthera announces positive Phase I/IIb data for ProtheraCytes® cell therapy in acute myocardial infarction
/*! elementor - v3.21.0 - 08-05-2024 */ .elementor-widget-image{text-align:center}.elementor-widget-image a{display:inline-block}.elementor-widget-image a img[src$=".svg"]{width:48px}.elementor-widget-image img{vertical-align:middle;display:inline-block} Positive changes in prognostic biomarkers including...